Conclusion of the contract for the phasing of the CT-01 project

Current report No. 16/2024

Date of preparation: 12.06.2024

Subject: Conclusion of the contract for the phasing of the CT-01 project

Legal basis: Article 17(1) MAR - confidential information.

With reference to current reports 55/2023 of November 13, 2023, 7/2024 of March 6, 2024 and 12/2024 of May 23, 2024 the Management Board of Captor Therapeutics S.A. based in Wroclaw ("Company"), announces that today it has concluded an agreement with the National Centre for Research and Development ("NCBR") for the funding of Stage II of the CT-01 project under the European Funds for the Modern Economy (FENG) programme (Discovery and development of a new clinical drug candidate for the eradication of cancer stem cell in the treatment of hepatocellular carcinoma, through degradation of oncofetal transcription factor – stage II).

In accordance with the Agreement, the amount of funding to be used from 1 January 2024, i.e. during the extended duration of the project, is PLN 6,766,157.95.

The Agreement contains standard provisions customary in NCBR public funding agreements.

The Company will inform for further proceedings as required by law.